{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:41:05Z","timestamp":1790912465953,"version":"4.1.0"},"reference-count":60,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2014,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Subunit vaccines against anthrax based on recombinant protective antigen (PA) potentially offer more consistent and less reactogenic anthrax vaccines but require adjuvants to achieve optimal immunogenicity. This study sought to determine in a murine model of pulmonary anthrax infection whether the polysaccharide adjuvant Advax or the innate immune adjuvant murabutide alone or together could enhance PA immunogenicity by comparison to an alum adjuvant. A single immunization with PA plus Advax adjuvant afforded significantly greater protection against aerosolized\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            Sterne strain 7702 than three immunizations with PA alone. Murabutide had a weaker adjuvant effect than Advax when used alone, but when murabutide was formulated together with Advax, an additive effect on immunogenicity and protection was observed, with complete protection after just two doses. The combined adjuvant formulation stimulated a robust, long-lasting B-cell memory response that protected mice against an aerosol challenge 18 months postimmunization with acceleration of the kinetics of the anamnestic IgG response to\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            as reflected by \u223c4-fold-higher anti-PA IgG titers by day 2 postchallenge versus mice that received PA with Alhydrogel. In addition, the combination of Advax plus murabutide induced approximately 3-fold-less inflammation than Alhydrogel as measured by\n            <jats:italic>in vivo<\/jats:italic>\n            imaging of cathepsin cleavage resulting from injection of ProSense 750. Thus, the combination of Advax and murabutide provided enhanced protection against inhalational anthrax with reduced localized inflammation, making this a promising next-generation anthrax vaccine adjuvanting strategy.\n          <\/jats:p>","DOI":"10.1128\/cvi.00019-14","type":"journal-article","created":{"date-parts":[[2014,2,20]],"date-time":"2014-02-20T06:03:19Z","timestamp":1392876199000},"page":"580-586","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":51,"title":["Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant"],"prefix":"10.1128","volume":"21","author":[{"given":"Brandon","family":"Feinen","sequence":"first","affiliation":[{"name":"Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolai","family":"Petrovsky","sequence":"additional","affiliation":[{"name":"Flinders Medical Centre and Vaxine Pty. Ltd., Bedford Park, South Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Verma","sequence":"additional","affiliation":[{"name":"Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tod J.","family":"Merkel","sequence":"additional","affiliation":[{"name":"Division of Bacterial, Parasitic and Allergenic Products, Center for Biologics Evaluation and Research, FDA, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.micro.55.1.647"},{"key":"e_1_3_2_3_2","first-page":"385","article-title":"The development of anthrax following the administration of spores by inhalation","volume":"28","author":"Barnes JM","year":"1947","unstructured":"BarnesJM. 1947. The development of anthrax following the administration of spores by inhalation. Br. J. Exp. Pathol. 28:385\u2013394.","journal-title":"Br. J. Exp. Pathol."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7973702"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020329"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2004.03.009"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"5545","DOI":"10.4049\/jimmunol.174.9.5545","article-title":"Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis","volume":"174","author":"Brittingham KC","year":"2005","unstructured":"BrittinghamKCRuthelGPanchalRGFullerCLRibotWJHooverTAYoungHAAndersonAOBavariS. 2005. Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J. Immunol. 174:5545\u20135552.","journal-title":"J. Immunol."},{"key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"7994","DOI":"10.4049\/jimmunol.178.12.7994","article-title":"Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route","volume":"178","author":"Cleret A","year":"2007","unstructured":"CleretAQuesnel-HellmannAVallon-EberhardAVerrierBJungSVidalDMathieuJTournierJN. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178:7994\u20138001.","journal-title":"J. Immunol."},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2958.2001.02695.x"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.1700730219"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1462-5822.2000.00067.x"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1462-5822.2006.00738.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.11.7495-7501.2005"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909093411107"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.75.103004.142728"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.280.5364.734"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1998.9040"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.62.10.4432-4439.1994"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.79.10.3162"},{"key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.4049\/jimmunol.174.8.4934","article-title":"Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells","volume":"174","author":"Tournier JN","year":"2005","unstructured":"TournierJNQuesnel-HellmannAMathieuJMontecuccoCTangWJMockMVidalDRGoossensPL. 2005. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174:4934\u20134941.","journal-title":"J. Immunol."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/iai.59.6.1961-1965.1991"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.23233"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00320-13"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.05.044"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.4161\/hv.3.5.4459"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2672.1999.00898.x"},{"key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.4049\/jimmunol.170.11.5636","article-title":"Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen","volume":"170","author":"Boyaka PN","year":"2003","unstructured":"BoyakaPNTafaroAFischerRLepplaSHFujihashiKMcGheeJR. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170:5636\u20135643.","journal-title":"J. Immunol."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-006-0206-9"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.0818-9641.2004.01272.x"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.30"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwq201"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/glycob\/cwt053"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.019190-0"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00480-13"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.021"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.023242-0"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.12.077"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2012.06.009"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2004.06.012"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/ni1207-1269"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200107)31:7<1962::AID-IMMU1962>3.0.CO;2-V"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2010.01.013"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1006\/cyto.1996.0088"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.17.7794-7802.2000"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2783"},{"key":"e_1_3_2_46_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/153.3.628"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.12.7967-7976.2005"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1179\/096805106X89044"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.crvi.2004.02.010"},{"key":"e_1_3_2_50_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2567.2001.01269.x"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200207010-00005"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041529"},{"key":"e_1_3_2_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2012.10.029"},{"key":"e_1_3_2_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(94)00094-5"},{"key":"e_1_3_2_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00633-08"},{"key":"e_1_3_2_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01875-06"},{"key":"e_1_3_2_57_2","doi-asserted-by":"publisher","DOI":"10.1038\/7933"},{"issue":"06","key":"e_1_3_2_58_2","first-page":"1","article-title":"Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009","volume":"59","author":"Wright JG","year":"2010","unstructured":"WrightJGQuinnCPShadomySMessonnierN. 2010. Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm. Rep. 59(rr06):1\u201330.","journal-title":"MMWR Recomm. Rep."},{"key":"e_1_3_2_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/0008-8749(89)90011-7"},{"key":"e_1_3_2_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.12.028"},{"key":"e_1_3_2_61_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.024"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00019-14","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00019-14","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:50:41Z","timestamp":1627591841000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00019-14"}},"subtitle":[],"editor":[{"given":"P. P.","family":"Wilkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["10.1128\/CVI.00019-14"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00019-14","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"2014-01-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-02-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-03-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}